A Comparison of the Effectiveness and Safety of Levofloxacin to That of Ciprofloxacin in Treating Complicated Urinary Tract Infection and Acute Pyelonephritis.

Urinary Tract Infections Clinical Trial

Official title:
A Multicenter, Double-blind, Randomized Study to Compare the Efficacy and Safety of Levofloxacin 750 mg Once Daily for Five Days Versus Ciprofloxacin Twice Daily for Ten Days in the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis.

Status Completed

Clinical Trial Summary

The purpose of this study is to evaluate the effectiveness and safety of two antibiotics in the treatment of complicated urinary tract infection or acute pyelonephritis (kidney infection). A 5-day course of 750 milligrams of levofloxacin given intravenously and/or by mouth once daily will be compared to a 10-day course of 400 milligrams of ciprofloxacin given intravenously and/or 500 milligrams of ciprofloxacin given by mouth twice daily.

Clinical Trial Description

Levofloxacin has been approved in both its oral and intravenous forms to treat a large number of infections caused by bacteria. Levofloxacin and other members of a class of antibiotics known as fluoroquinolones have been used successfully to treat urinary and kidney infections. This study will compare the effectiveness and safety of levofloxacin given for 5 days to that of another fluoroquinolone, ciprofloxacin, given for 10 days in treating complicated urinary tract infection or acute pyelonephritis (kidney infection). A shorter course of antibiotics may help patients take all of their medication, which is critically important for curing the infection. A shorter course may also help prevent the development of bacteria that cannot be killed by antibiotics. Patients will take 750 milligrams of levofloxacin intravenously and/or by mouth once daily for 5 days or 400 milligrams of ciprofloxacin intravenously and/or 500 milligrams of ciprofloxacin by mouth twice daily for 10 days. To prevent the study doctor, study staff and patients from knowing which study drug they are taking, all study drug will manufactured to look the same and patients on the 5-day regimen will be given placebo for the last 5 days of their participation in the study. The intravenous infusion bags will be covered so that the solution cannot be seen. The objective of the study is to demonstrate that 5 days of levofloxacin once daily is at least as effective as 10 days of ciprofloxacin twice daily in treating complicated urinary tract infection or acute pyelonephritis. Patients will take 750 milligrams of levofloxacin intravenously and/or by mouth once daily for 5 days or 400 milligrams of ciprofloxacin intravenously and/or 500 milligrams of ciprofloxacin by mouth twice daily for 10 days. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00210886
Study type	Interventional
Source	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Contact
Status	Completed
Phase	Phase 3
Start date	October 2004
Completion date	April 2006

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04495699` - Asymptomatic Renal Calculi in Recurrent Urinary Tract Infections
Terminated	`NCT05254808` - EXtended Use of FOsfomycin for the Treatment of CYstitis in Primary Care	Phase 3
Completed	`NCT03680612` - Cefepime/AAI101 Phase 2 Study in Hospitalized Adults With cUTI	Phase 2
Completed	`NCT03282006` - Treating Pyelonephritis an Urosepsis With Pivmecillinam	Phase 4
Completed	`NCT03526484` - The Utility of Urinalysis Prior to In-Office Procedures	N/A
Completed	`NCT05397782` - Effects of Flourish on Recurrent Urinary Tract Infection	N/A
Completed	`NCT05018546` - Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery	N/A
Completed	`NCT03687255` - Safety and Efficacy Study of Cefepime-AAI101 in the Treatment of Complicated Urinary Tract Infections	Phase 3
Recruiting	`NCT05227937` - Single Dose Amikacin for Uncomplicated Cystitis in the ED: A Feasibility Study
Completed	`NCT02864420` - Hospitalization at Home: The Acute Care Home Hospital Program for Adults	N/A
Completed	`NCT03131609` - Avoiding Bacterial Contamination of Clean Catch Urine Cultures in Ambulatory Patients in the Emergency Department
Completed	`NCT01911143` - A Retrospective, Blinded Validation of a Host-response Based Diagnostics	N/A
Completed	`NCT01333254` - A Trial of Different Methods for Bladder Drainage in Hip Surgery Patients	N/A
Terminated	`NCT00594594` - Adjuntive Probiotic Therapy in Treating Urinary Tract Infections in Spinal Cord Injury	Phase 1
Completed	`NCT00216853` - A Study of Vaginal MicroFlora and Immune Profiles of Patients With Recurrent Urinary Tract Infection	N/A
Completed	`NCT00787085` - The Significance of Funguria in Hospitalized Patients	N/A
Completed	`NCT05719753` - The Effectiveness of a Bacteriophobic Coating on Urinary Catheters	N/A
Recruiting	`NCT05415865` - The Effect of Local Anesthetic Solution in the Bladder Prior to Botox Injections in the Bladder	Phase 3
Not yet recruiting	`NCT05880329` - DIagnoSing Care hOme UTI Study
Recruiting	`NCT04615065` - Acutelines: a Large Data-/Biobank of Acute and Emergency Medicine